Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles

Octavian Bucur, Ph.D., M.D.

Title
Institution
Department
Address
Phone
Profile Picture

Biography
2017
Best Scientific Poster Award, Harvard Medical Pathology Retreat (1st from >100)
2017
Chair, Selection Committee, RALI Grand Rounds Competition, BIDMC, Boston, MA
2017
BIDMC's 10 Years of Pathology Dedicated Research Award, BIDMC, Boston, MA
2015
American Association for Cancer Research-Millennium Pharmaceuticals Award
2010
IUBMB Travel Award, YSF and OzBio2010 Conference, Melbourne, Australia
2008 - 2009
Lady Tata Memorial Trust Fellowship/Award, London, UK (elongation)
2008
American Association for Cancer Research-Aflac Award
2007 - 2008
Lady Tata Memorial Trust Fellowship/Award, London, UK
2004
EU - Leonardo da Vinci Research Fellowship (Max Planck Inst., Germany)
2003
Romanian Ministry of Education & Research Fellowship (Cleveland Clinic, USA)
2002
International Federation of Medical Students Associations Fellowship (Spain)
1999
Honorary Admission for exceptional accomplishments in Biology to the Medical School

Featured Content

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Zhao Y*, Bucur O*, Irshad H, Chen F, Weins A, Stancu AL, Oh EY, DiStasio M, Torous V, Glass B, Stillman IE, Schnitt SJ, Beck AH, Boyden ES. Nanoscale imaging of clinical specimens using pathology-optimized expansion microscopy. Nat Biotechnol. 2017.
  2. Bhasin MK, Ndebele K, Bucur O, Yee EU, Otu HH, Plati J, Bullock A, Gu X, Castan E, Zhang P, Najarian R, Muraru MS, Miksad R, Khosravi-Far R, Libermann TA. Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier. Oncotarget. 2016 Apr 26; 7(17):23263-81. PMID: 26993610.
    View in: PubMed
  3. Bucur O, Almasan A, Zubarev R, Friedman M, Nicolson GL, Sumazin P, Leabu M, Nikolajczyk BS, Avram D, Kunej T, Calin GA, Godwin AK, Adami HO, Zaphiropoulos PG, Richardson DR, Schmitt-Ulms G, Westerblad H, Keniry M, Grau GE, Carbonetto S, Stan RV, Popa-Wagner A, Takhar K, Baron BW, Galardy PJ, Yang F, Data D, Fadare O, Yeo KJ, Gabreanu GR, Andrei S, Soare GR, Nelson MA, Liehn EA. An updated h-index measures both the primary and total scientific output of a researcher. Discoveries. 2015; 3(3):e50.
  4. Oh EY, Christensen SM, Ghanta S, Jeong JC, Bucur O, Glass B, Montaser-Kouhsari L, Knoblauch NW, Bertos N, Saleh SM, Haibe-Kains B, Park M, Beck AH. Extensive rewiring of epithelial-stromal co-expression networks in breast cancer. Genome Biol. 2015 Jun 19; 16:128. PMID: 26087699; PMCID: PMC4471934.
  5. Bucur O, Gaidos G, Yatawara A, Pennarun B, Rupasinghe C, Roux J, Andrei S, Guo B, Panaitiu A, Pellegrini M, Mierke DF, Khosravi-Far R. A novel caspase 8 selective small molecule potentiates TRAIL-induced cell death. Sci Rep. 2015 May 11; 5:9893. PMID: 25962125; PMCID: PMC4426715.
  6. Irshad H, Montaser-Kouhsari L, Waltz G, Bucur O, Nowak JA, Dong F, Knoblauch NW, Beck AH. Crowdsourcing image annotation for nucleus detection and segmentation in computational pathology: evaluating experts, automated methods, and the crowd. Pac Symp Biocomput. 2015; 294-305. PMID: 25592590; PMCID: PMC4299942.
  7. Bucur O, Stancu AL, Muraru MS, Melet A, Petrescu SM, Khosravi-Far R. PLK1 is a binding partner and a negative regulator of FOXO3 tumor suppressor. Discoveries. 2014; 2(2):e16.
  8. Gunda V, Bucur O, Varnau J, Vanden Borre P, Bernasconi MJ, Khosravi-Far R, Parangi S. Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways. Cell Death Dis. 2014 Mar 06; 5:e1104. PMID: 24603332; PMCID: PMC3973207.
  9. Pennarun B, Gaidos G, Bucur O, Tinari A, Rupasinghe C, Jin T, Dewar R, Song K, Santos MT, Malorni W, Mierke D, Khosravi-Far R. killerFLIP: a novel lytic peptide specifically inducing cancer cell death. Cell Death Dis. 2013 Oct 31; 4:e894. PMID: 24176852; PMCID: PMC3920952.
  10. Bucur O, Stancu AL, Goganau I, Petrescu SM, Pennarun B, Bertomeu T, Dewar R, Khosravi-Far R. Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells. PLoS One. 2013; 8(10):e77390. PMID: 24155950; PMCID: PMC3796452.
  11. Bucur O, Pennarun B, Stancu AL, Nadler M, Muraru MS, Bertomeu T, Khosravi-Far R. Poor antibody validation is a challenge in biomedical research: a case study for detection of c-FLIP. Apoptosis. 2013 Oct; 18(10):1154-62. PMID: 23917691.
    View in: PubMed
  12. Liehn EA, Bucur O, Weber C. Role of microparticles as messengers enhancing stem cell activity after genetic engineering. Circ Res. 2012 Jul 20; 111(3):265-7. PMID: 22821904.
    View in: PubMed
  13. Bucur O, Stancu AL, Khosravi-Far R, Almasan A. Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications. Cell Death Dis. 2012 Feb 02; 3:e263. PMID: 22297295; PMCID: PMC3288344.
  14. Plati J, Bucur O, Khosravi-Far R. Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb). 2011 Apr; 3(4):279-96. PMID: 21340093; PMCID: PMC3130501.
  15. Singh A, Ye M, Bucur O, Zhu S, Tanya Santos M, Rabinovitz I, Wei W, Gao D, Hahn WC, Khosravi-Far R. Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Mol Biol Cell. 2010 Mar 15; 21(6):1140-52. PMID: 20110348.
    View in: PubMed
  16. Plati J, Bucur O, Khosravi-Far R. Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. J Cell Biochem. 2008 Jul 01; 104(4):1124-49. PMID: 18459149; PMCID: PMC2941905.
  17. Melet A, Song K, Bucur O, Jagani Z, Grassian AR, Khosravi-Far R. Apoptotic pathways in tumor progression and therapy. Adv Exp Med Biol. 2008; 615:47-79. PMID: 18437891.
    View in: PubMed
  18. Bucur O, Ray S, Bucur MC, Almasan A. APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy. Front Biosci. 2006 May 01; 11:1549-68. PMID: 16368536.
    View in: PubMed
  19. Ray S, Bucur O, Almasan A. Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor. Apoptosis. 2005 Dec; 10(6):1411-8. PMID: 16215673.
    View in: PubMed
  20. Bucur O, Nat R, Cretoiu D, Popescu LM. Phagocytosis of apoptotic cells by microglia in vitro. J Cell Mol Med. 2001 Oct-Dec; 5(4):438-41. PMID: 12067480.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Bucur's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (136)
Explore
_
Co-Authors (14)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_